BeiGene/Amgen’s DLL3/CD3 bispecific antibody is approved for domestic market launch
July 21, 2025
Source: drugdu
121
The CDE official website shows that BeiGene and Amgen's application for taratumumab injection has been accepted for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have failed at least 2 lines of treatment (including platinum-containing chemotherapy). This indication has been included in the priority review. Globally, only one DLL3/CD3 dual antibody, taratumumab, has been approved for marketing. In addition, there are 4 other products that have entered the clinical stage, with the highest progress being clinical phase II. In terms of clinical progress, taratumumab has a first-mover advantage.
https://finance.sina.com.cn/roll/2025-07-17/doc-infftyiu0311325.shtml
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
